

# PHAYM001: Preparation for professional practice

[View Online](#)

---

[1]

A. R. Maher, 'Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults A Systematic Review and Meta-analysis', JAMA: The Journal of the American Medical Association, vol. 306, no. 12, Sep. 2011, doi: 10.1001/jama.2011.1360.

[2]

'Clinical guidelines, CG42 - Issued: November 2006'. [Online]. Available: <http://guidance.nice.org.uk/CG42>

[3]

'TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: guidance (MS Word format)'. [Online]. Available: <http://guidance.nice.org.uk/TA217/Guidance/doc/English>

[4]

'Exelon - Summary of Product Characteristics (SPC) - (eMC)'. [Online]. Available: <https://www.medicines.org.uk/emc/search?q=Exelon+>

[5]

'Aricept Tablets - Summary of Product Characteristics (SPC) - (eMC)'. [Online]. Available: <http://www.medicines.org.uk/emc/medicine/577/SPC/Aricept>

[6]

'Reminyl Tablets - Summary of Product Characteristics (SPC) - (eMC)'. .

[7]

'Ebixa 5mg/pump actuation oral solution, 20mg and 10 mg Tablets and Treatment Initiation Pack - Summary of Product Characteristics (SPC) - (eMC)'. [Online]. Available: <http://www.medicines.org.uk/EMC/medicine/10175/SPC/rEbixa+5mg+pump+oral+solution%252c+20mg+and+10+mg+tablets+and+Treatment+Initiation+Pack/>

[8]

'DH Living well with dementia: a National Dementia Strategy'. [Online]. Available: <https://www.gov.uk/government/organisations/department-of-health>

[9]

'British National Formulary'. [Online]. Available: <http://www.bnf.org/bnf/index.htm>

[10]

M. Bhasin, E. Rowan, K. Edwards, and I. McKeith, 'Cholinesterase inhibitors in dementia with Lewy bodies—a comparative analysis', *International Journal of Geriatric Psychiatry*, vol. 22, no. 9, pp. 890–895, Sep. 2007, doi: 10.1002/gps.1759.

[11]

H. Kavirajan and L. S. Schneider, 'Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials', *The Lancet Neurology*, vol. 6, no. 9, pp. 782–792, Sep. 2007, doi: 10.1016/S1474-4422(07)70195-3.

[12]

J. Warner and T. Smith, 'The rise and fall of antipsychotic prescribing in dementia. Where do we go from here?', *The rise and fall of antipsychotic prescribing in dementia*, vol. 14, no. 2, pp. 24–27.

[13]

Sube Banerjee, 'The use of antipsychotic medication for people with dementia: Time for action. A report for the Minister of State for Care Services'. 12AD [Online]. Available: <http://psychrights.org/research/digest/nlps/BanerjeeReportOnGeriatricNeurolepticUse.pdf>

[14]

'Optimising treatment and care for behavioural and psychological symptoms of dementia: A best practice guide'. [Online]. Available: <https://www.alzheimers.org.uk/bpsdguide>

[15]

'Treatment protocol by NHS Medway: Treatment of Behaviour That Challenges'. [Online]. Available: <http://www.kmpt.nhs.uk/policies>

[16]

'Antipsychotics increase mortality in elderly patients with dementia'. [Online]. Available: [http://www.npc.nhs.uk/merec/cns/dementia/merec\\_extra\\_no39.php](http://www.npc.nhs.uk/merec/cns/dementia/merec_extra_no39.php)

[17]

'Electronic Medicines Compendium (eMC)'. [Online]. Available: <http://www.medicines.org.uk/emc/>

[18]

Pierre N. Tariot, M.D.; Rosemary Erb, R.N., B.S.N.; Carol Ann Podgorski, Ph.D.; Christopher Cox, Ph.D.; Shirish Patel, M.D.; Laura Jakimovich, M.S., R.N.; Carrie Irvine, B.A., 'Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia', PsychiatryOnline | American Journal of Psychiatry | Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia, vol. 155, no. 1, pp. 54-61, 1998, doi: 10.1176/ajp.155.1.54.

[19]

G. Martínón-Torres, M. Fioravanti, and J. Grimley Evans, 'Trazodone for agitation in dementia', Cochrane Database of Systematic Reviews, Jul. 2004, doi: 10.1002/14651858.CD004990.

[20]

'Electronic Medicines Compendium (eMC)'. [Online]. Available: <http://www.medicines.org.uk/emc/>

[21]

'Risperdal Tablets, Liquid & Quicklet - Summary of Product Characteristics (SPC) - (eMC)'. [Online]. Available: <http://www.medicines.org.uk/emc/document.aspx?documentid=12818&docType=SPC>

[22]

A. R. Maher et al., 'Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults', JAMA, vol. 306, no. 12, Sep. 2011, doi: 10.1001/jama.2011.1360.

[23]

'Complete Guide to Behavioural and Psychological symptoms of Dementia'. [Online]. Available: <http://www.ipa-online.org/>

[24]

G. Waldemar, M. Hyvärinen, M. K. Josiassen, A. Kørner, H. Lehto, and P. Wetterberg, 'Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease', International Journal of Geriatric Psychiatry, vol. 23, no. 9, pp. 979-981, Sep. 2008, doi: 10.1002/gps.1979.

[25]

'Electronic Medicines Compendium (eMC)'. [Online]. Available: <https://www.medicines.org.uk/emc/>

[26]

'Evidence Search - Search Engine for Evidence in Health and Social Care'. [Online]. Available: <https://www.evidence.nhs.uk/>

[27]

'Evidence Search - Search Engine for Evidence in Health and Social Care'. [Online]. Available: <https://www.evidence.nhs.uk/>

[28]

'Map of Medicine | Home'. [Online]. Available: <http://www.mapofmedicine.com/>

[29]

'Medicines Information - Evidence Search - Search Engine for Evidence in Health and Social Care'. [Online]. Available: <https://www.evidence.nhs.uk/>

[30]

'NPC | National Prescribing Centre'. [Online]. Available: <https://www.guidelinesinpractice.co.uk>

[31]

'National Institute for Health and Care Excellence'. [Online]. Available: <http://www.nice.org.uk/>

[32]

'NICE Clinical Knowledge Summaries (CKS)'. [Online]. Available: <http://cks.nice.org.uk/>

[33]

'Scottish Intercollegiate Guidelines Network (SIGN)'. [Online]. Available: <http://www.sign.ac.uk/>

[34]

'Centre for Medicines Optimisation - MTRAC | Independent Medicines Review | Midlands Therapeutics Review & Advisory Committee | Centre for Medicines Optimisation | Keele University'. [Online]. Available: <http://centreformedicinesoptimisation.co.uk/mtrac/>

[35]

'NPC | National Prescribing Centre'. [Online]. Available: <https://www.guidelinesinpractice.co.uk>

[36]

'Evidence Search - Search Engine for Evidence in Health and Social Care'. [Online]. Available: <https://www.evidence.nhs.uk/>

[37]

'GOV.UK'. [Online]. Available: <https://www.gov.uk/government/organisations/department-of-health>

[38]

W. R. Miller and S. Rollnick, *Motivational interviewing: helping people change*, 3rd ed., vol. Applications of motivational interviewing. New York: Guilford Press, 2013.

[39]

J. O. Prochaska, J. C. Norcross, and C. C. DiClemente, *Changing for good*. New York: William Morrow, 1994.

[40]

S. Rollnick, P. Mason, and C. Butler, *Health behavior change: a guide for practitioners*. Edinburgh: Churchill Livingstone, 1999.

[41]

S. Rollnick, W. R. Miller, and C. Butler, *Motivational interviewing in health care: helping patients change behavior*, vol. *Applications of motivational interviewing*. New York: Guilford Press, 2008.

[42]

J. Hubley, J. Copeman, and J. Woodall, *Practical health promotion*, 2nd ed. Cambridge: Polity Press, 2013.

[43]

G. Laverack, *Health promotion practice: building empowered communities*. Maidenhead: Open University Press, 2007 [Online]. Available:  
<https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=nlebk&AN=234222&site=ehost-live&scope=site&custid=s8454451>

[44]

W. Macdowall, C. Bonell, and M. Davies, *Health promotion practice*, vol. *Understanding public health*. Maidenhead: Open University Press, 2006.

[45]

R. Walker and C. Whittlesea, *Clinical pharmacy and therapeutics*, 5th ed. Edinburgh: Churchill Livingstone, 2012 [Online]. Available:  
<https://www.vlebooks.com/Product/Index/173020?page=0&startBookmarkId=-1>

[46]

P. J. Kumar and M. L. Clark, *Kumar & Clark's clinical medicine*, 8th ed. Edinburgh: Saunders Elsevier, 2012 [Online]. Available: <https://www.dawsonera.com/abstract/9780702053047>

[47]

R. J. Greene and N. D. Harris, *Pathology and therapeutics for pharmacists: a basis for clinical pharmacy practice*, 3rd ed. London: Pharmaceutical Press, 2008.

[48]

'Coeliac disease: recognition, assessment and management | Guidance and guidelines | NICE' [Online]. Available: <https://www.nice.org.uk/guidance/ng20>

[49]

'Chronic obstructive pulmonary disease'. [Online]. Available: <http://cks.nice.org.uk/chronic-obstructive-pulmonary-disease>

[50]

'CPPE - Centre for Pharmacy Postgraduate Education'. [Online]. Available: <https://www.cppe.ac.uk/>

[51]

'Royal Pharmaceutical Society (RPS)'. [Online]. Available: <http://www.rpharms.com/home/home.asp>

[52]

'Heart failure - chronic'. [Online]. Available: <http://cks.nice.org.uk/heart-failure-chronic>

[53]

'Medicines Use Review and Prescription Intervention service'. [Online]. Available: [http://psnc.org.uk/wp-content/uploads/2013/06/MUR-service-spec-Aug-2013-changes\\_FINAL.pdf](http://psnc.org.uk/wp-content/uploads/2013/06/MUR-service-spec-Aug-2013-changes_FINAL.pdf)

[54]

'Service specification - New Medicine Service (NMS)'. [Online]. Available: [http://psnc.org.uk/wp-content/uploads/2013/06/NMS-service-spec-Aug-2013-changes\\_FINAL.pdf](http://psnc.org.uk/wp-content/uploads/2013/06/NMS-service-spec-Aug-2013-changes_FINAL.pdf)

[55]

'Commissioners and healthcare professionals - Training videos'. [Online]. Available:  
[http://healthcheck.nhs.uk/commissioners\\_and\\_providers/training/training\\_videos1/](http://healthcheck.nhs.uk/commissioners_and_providers/training/training_videos1/)

[56]

'NHS Health Check - NHS Choices'. [Online]. Available:  
<http://www.nhs.uk/Conditions/nhs-health-check/Pages/NHS-Health-Check.aspx>